References
- John Hopkins University 2022. John Hopkins University, coronavirus resource center, mortality analysis; [cited 2023 March 1]. Avaialble from: https://coronavirus.jhu.edu/data/mortality.
- Sciensano. Belgium COVID-19 epidemiological situation. Bruxelles (BE):Sciensano;2022 [cited 2023 March 1]. Available from: https://datastudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/ZwmOB.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with covid-19. N Engl J Med. 2021;385(23):e81. DOI:10.1056/NEJMoa2108163
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246. DOI:10.1001/jama.2022.2832
- Huang DT, McCreary EK, Bariola JR, et al. Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 delta variant surge: a cohort study and randomized comparative effectiveness trial. JAMA Netw Open. 2022;5(7):e2220957. DOI:10.1001/jamanetworkopen.2022.20957
- Solera JT, Árbol BG, Alshahrani A, et al. Impact of vaccination and early monoclonal antibody therapy on COVID-19 outcomes in organ transplant recipients during the omicron wave. Clin Infect Dis. 2022;75(12):2193–2200.
- Moniteur belge du 19 mai 2021. Bruxelles(be): service public fédéral justice. 2022 [Belgian official journal of 19 May 2021. Brussels (BE): federal public service justice] [cited 2022 Oct 23]. French. Available from: https://www.afmps.be/sites/default/files/MB%20publicatie.pdf
- Sciensano. Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium. Bruxelles (BE):Sciensano. 2022 [cited 2022 Oct 23]. Available from:https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf.
- Moniteur belge du 28 septembre 2021. Bruxelles (BE): service public fédéral justice; [Belgian official journal of 28 September 2021. Brussels (BE)]: federal public service justice]; 2022 [cited 2022 Oct 23). French. Available from https://www.ejustice.just.fgov.be/mopdf/2021/10/04_1.pdf#Page238Moniteur belge du 28 septembre 2021.
- Bierle DM, Ganesh R, Tulledge-Scheitel S, et al. Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities. J Infect Dis. 2022;225(4):598–602. DOI:10.1093/infdis/jiab570
- Fernandes G, Devresse A, Scohy A, et al. Monoclonal antibody therapy for SARS-CoV-2 infection in kidney transplant recipients: a case series from Belgium. Transplantation. 2022;106(1):e107–108. DOI:10.1097/TP.0000000000003974
- CHU Charleroi-ISPPC. La Thérapie par anticorps monoclonaux neutralisants au CHU de Charleroi-ISPPC; [Neutralising monoclonal antibody therapy at the university hospital of Charleroi-ISPPC]. French. Available from: https://www.youtube.com/watch?v=tdx0VeDV9R8
- Xevudy-EPAR medicine review. Amsterdam (Nl):EMA;2022 [cited 2022 Aug 24]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy.
- Chavarot N, Melenotte C, Amrouche L, et al. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with omicron infection. Kidney Int. 2022;101(6):1290–1293. DOI:10.1016/j.kint.2022.04.003
- Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis. 2021;224(8):1278–1286. DOI:10.1093/infdis/jiab377
- Genomic surveillance of SARS-CoV-2 in Belgium [cited 2023 Feb 28]. Available from: https://www.uzleuven.be/nl/laboratoriumgeneeskunde/genomic-surveillance-sars-cov-2-belgium
- Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):8991. 5 jan 2023. DOI:10.1056/NEJMc2214302.